Preclinical Studies in Drug Development Testing and Studies

TD2's highly specialized oncology drug development team enlists an integrated suite of cutting-edge tools built around cellular pathway interrogation, combination strategies, and the identification of mutational contexts to inform clinical development plans.

TD2 is an AAALAC-accredited facility and focuses its preclinical efforts on: non-GLP safety/tolerability, in vitro assays, DMPK services, tumor xenograft models, patient-derived tumor xenograft models, syngeneic tumor models, and orthotopic tumor models.

The preclinical team has extensive experience working with all types of molecules, including small molecules and biologics (immunoconjugates, peptides, antibodies, siRNAs and miRNAs), and is well equipped to execute studies to demonstrate efficacy in both single agent and combination settings.

A dedicated project manager is assigned to every preclinical study to provide regular updates, facilitate the flow of information, and oversee the implementation of mid-study changes.

Read about case studies